That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
Early human trials of an experimental injection called CBL-514 have shown promise in reducing dangerous visceral fat by 12% on average after four weeks. Conducted by researchers at the University of Alabama at Birmingham and Caliway Biopharmaceuticals, the study involved participants receiving injections every three weeks for up to 12 weeks, with doses ranging up to 600 milligrams based on abdominal fat thickness. MRI scans revealed that visceral fat decreased in those who received CBL-514 while increasing in a placebo group. The injection works by selectively causing apoptosis—cell self-destruction—in fat cells without harming surrounding tissues.
Written locally by qwen2.5:14b on 2026-10-11,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
Early human trials of an experimental injection called CBL-514 have shown promise in reducing dangerous visceral fat deposits. Conducted by Dr. W. Timothy Garvey from the University of Alabama at Birmingham and Yu-Fang Ling from Caliway Biopharmaceuticals in New Taipei City, Taiwan, these studies involved administering 600 milligrams of CBL-514 to participants every three weeks for up to 12 weeks via injections into their lower abdomen. MRI scans revealed that those receiving the injection experienced a 12% reduction in visceral fat compared to an increase among those given a placebo. This development is significant as visceral fat, located deep inside the abdomen around internal organs, impacts metabolism and can contribute to insulin resistance and type 2 diabetes. The research also aligns with previous findings by the American Heart Association that indicated visceral fat has a stronger association with heart failure risk than BMI.
Written for “Belly Fat Injection Trial” on 2026-10-12,
grounded in this article and the 0 other(s) covering the same event.
Early human trials of an experimental injection called CBL-514 have shown potential for reducing deadly visceral fat.
asserted
trials → call → fat
Visceral fat, which sits deep inside the abdomen wrapped around internal organs, affects metabolism, influences insulin resistance and can impact the development of type 2 diabetes.
asserted
which → sit → diabetes
Research published in March by the American Heart Association found that visceral fat had a stronger association with the risk of heart failure than body mass index (BMI).
asserted
fat → publish → index
The trials tested whether the injection could diminish visceral fat deposits, and they were conducted by Dr. W. Timothy Garvey of the University of Alabama at Birmingham and Yu-Fang Ling of Caliway Biopharmaceuticals in New Taipei City, Taiwan.
uncertain
they → test → City
Previous phase 2 trials had already shown that the drug could reduce subcutaneous fat, the layer of fat directly beneath the skin.
uncertain
drug → show → skin
MRI scans from two phase 2 trials exhibited a decrease in visceral fat in participants who received the CBL-514 drug, while the visceral fat increased in those who received a placebo drug.
asserted
who → exhibit → drug
Participants who were given CBL-514 received injections into their lower abdomen every three weeks for up to 12 weeks, with doses of up to 600 milligrams.
asserted
who → give → milligrams
The number of injections given to participants depended on the thickness of their abdominal fat.
asserted
number → give → fat
As the fat layer decreased in volume, the number of injections also decreased.
asserted
number → decrease → injections
The CBL-514 injection selectively sparks apoptosis—a process which causes cells to self-destruct—but only in fat cells, leaving nearby cells unharmed.
asserted
cells → spark → cells
Four weeks after the final treatment, the average volume of fat had lowered by 12.01% in the group given CBL-514, while it had increased by 5.68% in the group that received a placebo, SciTechDaily reported.
asserted
SciTechDaily → lower → placebo
The potential cosmetic effects, such as a flatter stomach due to subcutaneous fat loss, are appealing to patients, Garvey acknowledged.
asserted
Garvey → appeal → patients
However, what’s even more important, he noted, is the decrease in body weight, improved blood pressure and cholesterol, and the loss of visceral fat that the injection can cause, as these factors impact overall health.
asserted
factors → ’ → health
Liposuction, a common surgical cosmetic procedure, cannot remove visceral fat, and thus cannot reduce the health risks caused by a high amount of visceral fat.
asserted
Liposuction → remove → fat
The Aporia
